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Halofuginone is a drug that has been shown to have
an anti®brotic property in vitro and in vivo. Whereas
halofuginone shows promise as a therapeutic agent
for a variety of diseases including scleroderma, liver
cirrhosis, cystic ®brosis, and certain types of cancer,
the mechanism of action remains unknown. Using
the tight skin mouse (TSK) model for scleroderma,
we evaluated the ability of halofuginone to inhibit
spontaneous development of dermal ®brosis. We
found that administration of a low dose of halo-
fuginone both in adult and newborn animals for 60 d
prevented the development of cutaneous hyperplasia
(dermal ®brosis). In vitro halofuginone was found to
reduce the amount of collagen synthesized by ®bro-
blasts. This effect was due to a reduction in the
promoter activity of the type-I collagen genes as
treatment of ®broblast cultures with 10±8 M halofugi-
none reduced the level of a2(I) collagen message
detectible by northern blot and greatly reduced the
activity of a reporter construct under control of the
±3200 to +54 bp a2(I) collagen promoter. In addi-
tion, analysis of transforming growth factor b signal-
ing pathways in ®broblasts revealed that
halofuginone inhibited transforming-growth-factor-
b-induced upregulation of collagen protein and
activity of the a2(I) collagen promoter. Further we
found that halofuginone blocked the phosphorylation
and subsequent activation of Smad3 after transform-
ing growth factor b stimulation. Apparently the
inhibitory property was speci®c to Smad3 as there
was no inhibitory effect on the activation of Smad2
after stimulation with transforming growth factor b.
Our results demonstrate that halofuginone is a
speci®c inhibitor of type-I collagen synthesis and
may elicit its effect via interference with the trans-
forming growth factor b signaling pathway. Key
words: ®brosis/scleroderma/signal transduction/TGF-b/
tight skin. J Invest Dermatol 118:461±470, 2002
S
cleroderma is an idiopathic disorder characterized by
over-synthesis and deposition of collagen leading to
®brosis of the skin and other internal organs (Steen,
1998). The etiology of the disease is unknown, but both
genetic and environmental factors have been implicated
(Fanning et al, 1998; Steen, 1998; Tan et al, 1998). Recently it was
reported that halofuginone causes a drastic reduction in the skin
tensile strength of broiler chickens and inhibits the synthesis of
collagen type I in avian, murine, and human ®broblasts (Granot
et al, 1991, 1993; Halevy et al, 1996). Subsequently it was found
that halofuginone also inhibited the expression of the matrix
metalloproteinase 2 (MMP-2) gene and angiogenesis associated
with bladder carcinoma metastasis (Elkin et al, 1999). These
®ndings indicated that halofuginone may have important clinical
applications in diseases such as scleroderma, a disorder in which
®brosis plays a signi®cant role in morbidity and mortality (Liu and
Connolly, 1998; Steen, 1998). In spite of the tremendous potential
bene®t of this drug, however, little research has been invested in
understanding its mechanism of action.
Several lines of evidence link transforming growth factor b
(TGF-b) stimulation with the regulation of extracellular matrix
protein production. First TGF-b stimulation has been shown to
upregulate the production of collagen types I, III, and VII (Uitto et
al, 1979; Kulozik et al, 1990; Inagaki et al, 1994; Yoshiro et al, 1997;
Vindevoghel et al, 1998), and ®bronectin (Hocevar et al, 1999), and
to regulate the expression of several MMPs including MMP-1,
MMP-2, MMP-3, and MMP-13 (Kubota et al, 1991; Uria et al,
1998). Second, increased TGF-b production has been observed in
several human disorders associated with connective tissue ®brosis.
For instance, immunohistochemical analysis of biopsies from the
lesions of scleroderma patients demonstrated the increased presence
of cells producing TGF-b (Gay et al, 1992; S®kakis et al, 1993;
Higley et al, 1994). In addition, Arkwright et al (2000) found a
strong association between the overproduction of TGF-b and an
accelerated decline in lung function in cystic ®brosis patients.
Finally, several groups have shown a direct correlation between the
inhibition of TGF-b and the abrogation of ®brosis in the skin and
lung. In two notable examples, bleomycin-induced lung ®brosis
was prevented in mice by the introduction of the inhibitory Smad7
gene via in vivo DNA transfection (Nakao et al, 1999), and the
administration of anti-TGF-b antibodies prevented cutaneous
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hyperplasia in a model for chronic graft versus host disease
(McCormick et al, 1999). Likewise, our laboratory has found that
disruption of the TGF-b gene prevented skin ®brosis in tight skin
(TSK) mice (McGaha et al, 2001).
In this study we examined the effect of halofuginone on skin
®brosis and TGF-b signaling pathways leading to the upregulation
of collagen gene expression. We found that halofuginone pre-
vented dermal ®brosis in TSK mice. Additionally, we found that
treatment of ®broblasts with 10±8 M halofuginone totally inhibited
collagen protein and a2(I) collagen mRNA production.
Furthermore, analysis of TGF-b signaling pathways demonstrated
that halofuginone inhibited DNA binding and nuclear localization
of Smad3 after TGF-b stimulation and that this effect is due to the
inhibition of Smad3 phosphorylation. To our knowledge, this is the
®rst compound shown to directly inhibit TGF-b-induced Smad
signaling, and in this respect halofuginone may become important
not only as a therapeutic agent for some connective tissue diseases
but as a basic research tool in TGF-b biology.
MATERIALS AND METHODS
Cell lines and cell culture conditions Primary ®broblast lines were
generated as previously described (McGaha et al, 2001). Brie¯y, 9-d-old
embryos were minced and incubated for 30 min at room temperature in
Hanks' balanced salt solution containing 0.25% bovine pancreatic trypsin
(Mediatech, Herndon, VA). The cells were collected and incubated for
three passages in Dulbecco's modi®ed Eagle's medium (DMEM)/F12
medium (Mediatech) containing 20% fetal bovine serum (Atlanta
Biologicals, Atlanta, GA). The TSK ®broblasts were genotyped to
con®rm the presence of the partially duplicated ®brillin-1 gene (Kasturi
et al, 1997). From the third passage on all primary ®broblast lines were
maintained in DMEM supplemented with 100 U per ml penicillin/
100 mg per ml streptomycin and 10% fetal bovine serum (Mediatech).
Primary ®broblasts were used in experiments from the third to the tenth
passage only.
Mice and in vivo halofuginone treatment Newborn or 4-wk-old
male TSK and C57BL/6 mice bred at the Mount Sinai Animal Facility
were used in all experiments. For the in vivo treatment 1 mg of
halofuginone (a gift from Hoechst Marion Roussel, Puteaux, France) in
500 ml of sterile phosphate-buffered saline (PBS) or 500 ml of PBS alone
was administered via intraperitoneal injection to TSK and C57BL/6
mice once every other day for 60 d. At the end of the treatment period
the animals were sacri®ced and skin and lung samples were removed for
analysis of the effect of halofuginone on TSK syndrome.
Histologic examination Skin samples (4.0 cm2) were removed from
the dorsal side immediately below the neck in a manner that minimized
stress. The samples were ®xed for 16 h in buffered saline containing
formalin, cut into 2±3 mm wide longitudinal strips, dehydrated,
embedded in paraf®n, and stained with hematoxylin±eosin according to
routine histologic methods. The thickness of the skin was determined by
measuring at least 12 randomly selected sections from the top of the
granular layer to the junction between the dermis and subcutaneous fat
on hematoxylin±eosin-stained sections as previously described (Phelps
et al, 1993).
Cell proliferation and 35S incorporation To determine the effects of
halofuginone on cell growth 103, 5 3 103, or 104 ®broblasts were plated
in 96-well plates. After a 4 h incubation halofuginone was added and the
cells were allowed to grow at 37°C for 24, 48, or 72 h. The number of
cells present was then determined using the Cell Titer Proliferation Assay
(Promega, Madison, WI) according to the manufacturer's directions.
For the determination of the effect of halofuginone on protein
synthesis 105 ®broblasts were plated in 60 mm2 plates. After a 24 h
incubation the medium was replaced with serum-free DMEM lacking
the amino acid methionine 6 halofuginone. Twenty-four hours after the
addition of halofuginone 50 mCi of 35S-labeled methionine (Amersham,
Piscataway, NJ) was added for a 4 h incubation. The cells were then
lyzed with RIPA buffer as described elsewhere in this section. The
proteins were precipitated with trichloroacetic acid (Peterkofsky and
Diegelmann, 1971), washed twice with 70% EtOH, and resuspended in
50 ml RIPA. Protein concentration was determined using the Dc Protein
Assay (Biorad) and the level of 35S-Met incorporation was determined
with a scintillation counter.
Measurement of collagen synthesis Fibroblasts were grown to
con¯uence in 75 cm2 ¯asks, detached via trypsinization, and plated at a
density of 105 cells per well in 24-well plates. After 24 h the ®broblasts
were washed with PBS and the medium was replaced with proline-free
DMEM supplemented with 3 mCi per well 3H-proline (Amersham),
50 mg per ml ascorbic acid, 50 mg per ml b-aminopropionitrile, and
halofuginone 6 10 ng per ml TGF-b. After a 24 h incubation, the
medium was collected for determination of collagen synthesis and the
cell numbers were counted. To measure collagen synthesis, 100 ml
aliquots of medium from labeled ®broblasts were incubated at 37°C for
18 h in either the presence or absence of highly puri®ed bacterial
collagenase (Sigma, St. Louis, MO) at a concentration of 200 U per
aliquot. The samples were then extensively dialyzed in microdialysis
chambers (Pierce, Rockford, IL) against PBS at 4°C to remove
unincorporated 3H-proline and digested collagen. The total counts per
sample were then determined utilizing a liquid scintillation counter.
Biosynthetic labeling of collagen was estimated by subtracting the counts
per minute of the collagenase-digested aliquot from the counts per
minute of the aliquot without collagenase added.
Electrophoretic mobility shift assay (EMSA) EMSA was performed
according to protocols previously described (Funk et al, 1992). Brie¯y,
con¯uent 100 mm2 plates of ®broblasts were incubated for 16 h with
10±8 M halofuginone in 3 ml of serum-free DMEM. The ®broblasts
were then stimulated for 30 min with 10 ng per ml of recombinant
human (rh) TGF-b1 (R&D Systems, Minneapolis, MN). At the end of
this period nuclear extracts were generated as previously described by
Funk et al (1992). Ten micrograms of nuclear extract were incubated for
10 min at room temperature in binding buffer containing 20 mM
HEPES, 83.3 mM NaCl, 0.1 mM ethylenediamine tetraacetic acid
(EDTA), 10% glycerol, 1.9 mM MgCl2, 0.5 mM dithiothreitol, 0.01%
Triton X-100, and 25 mg per ml poly(dI-dC) (Sigma Aldrich) in either
the presence or absence of 40 ng of the unlabeled competitor
oligonucleotide OCT-1 or Smad3 (Santa Cruz Biotechnology, Santa
Cruz, CA). One nanogram of radiolabeled oligonucleotide (200,000
cpm) containing the Smad3 consensus binding site CAGACA (Santa
Cruz) was added and the binding reaction was incubated for 20 min at
room temperature. The samples were then loaded on a 4%
nondenaturing gel and electrophoresed for 3 h at 200 V. The shifted
bands were visualized by autoradiographic exposure for 6 h at ±70°C.
Smad3 nuclear localization Con¯uent TSK ®broblasts in 100 mm2
plates were serum starved for 16 h in the presence of 10±8 M
halofuginone. The ®broblasts were then stimulated with 10 ng per ml of
rhTGF-b1 for 5 min to 1 h at 37°C. Nuclear extracts were obtained as
previously described (Funk et al, 1992). Fifty micrograms of nuclear
extract were electrophoresed on a denaturing 12% polyacrylamide gel for
2 h at 100 V. The proteins were electro-transferred to a polyvinylidene
di¯uoride (PVDF) membrane (Millipore, Bedford, MA). The PVDF
membrane was then blocked with a solution of TBST [TBS containing
0.05% Tween-20 (Sigma)] containing 3% nonfat milk overnight at 4°C.
The PVDF membrane was probed with 1 mg per ml of polyclonal rabbit
anti-Smad3 (Santa Cruz) for 1 h at room temperature. The membrane
was then washed 3 3 10 min with TBST and probed with a 1:5000
dilution of polyclonal goat antirabbit IgG horseradish peroxidase
conjugate (Chemicon, Temecula, CA) for 30 min at room temperature.
The membrane was washed as above and the stained bands were
visualized with Lumi-Light plus chemiluminescent substrate (Boehringer
Mannheim, Indianapolis, IN) according to the manufacturer's
instructions.
Western blot analysis To analyze the phosphorylation of the TGF-
bRI or the PDGFR-AA con¯uent ®broblast culture was serum starved
for 16 h and stimulated with 10 ng per ml rhPDGF-AA or TGF-b1
(R&D Systems) for 10 min or 30 min. The ®broblasts were then lyzed
with RIPA buffer [TBS, 1% Nonidet P-40, 0.1% sodium dodecyl sulfate
(SDS), 100 mg per ml phenylmethylsulfonyl ¯uoride, 1 mM sodium
orthovanadate, 1:100 dilution of protease and phosphatase inhibitor
cocktails (Sigma)] and 200 mg of cellular lysate was incubated overnight
with 1 mg per ml of polyclonal rabbit a-PDGFR-AA or a-TGF-bRI
(Santa Cruz). The ab±ag complexes were precipitated with 50 ml of a
protein A:agarose and the proteins were separated on a 12% SDS
polyacrylamide gel. Western blot analysis of the TYR-phosphorylation
of the immunoprecipitated PDGFR-AA was then carried out as
described above using a mouse monoclonal a-phospho-TYR ab (Cell
Signaling Technology, Beverly, MA), and SER-phosphorylation of the
immunoprecipitated TGF-bRI was carried out with a goat polyclonal
a-phospho-SER ab (Zymed Laboratories, San Francisco, CA) according
to the manufacturer's directions.
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For analysis of TGF-b receptor expression and Smad2 phosphorylation
con¯uent ®broblast cultures were treated with halofuginone for 16 h in
serum-free conditions. The ®broblasts were stimulated with 10 ng per ml
of TGF-b (R&D Systems) and the cells were lyzed in RIPA buffer. A
hundred micrograms of protein were then electrophoresed on a 12%
SDS polyacrylamide gel and analyzed via western blot as described above
with 1 mg per ml of polyclonal rabbit a-phospho-Smad2 or aSmad2
(Upstate Biotechnology), a-TGF-bRII, a-TGF-bRI, or a-b-actin
(Santa Cruz).
32P incorporation assay As TSK ®broblasts do not express enough
endogenous Smad3 to visualize 32P incorporation in this assay (data not
shown), we transfected the ®broblasts with a Smad3:FLAG expression
construct (a gift from Maria Trojanowska). Con¯uent 60 mm2 plates of
TSK ®broblasts were transfected with 20 mg of the Smad3:FLAG vector
using Fugene6 transfection reagent (Roche, Indianapolis, IN) according
to the manufacturer's directions. It was previously determined that this
gave the highest levels of Smad3:FLAG expression (data not shown).
The transfected ®broblasts were incubated for 48 h to allow expression
of the recombinant protein. The ®broblasts were then serum starved for
16 h in the presence of 10±8 M halofuginone. At the end of this period
the ®broblasts were incubated for 4 h at 37°C with 1 ml of phosphate-
free DMEM (Mediatech) followed by an incubation with 1 mCi per ml
of 32P-labeled orthophosphate (Amersham) for 2 h. The cells were
washed twice with PBS and placed in 1 ml of serum-free DMEM. After
a 30 min incubation with 10 ng per ml rhTGF-b1 (R&D Systems) the
cells were lyzed with 0.4 ml of RIPA buffer. One microgram of
monoclonal anti-FLAG IgG (Sigma) was added to 250 mg of lysate in
500 ml of RIPA buffer and the solution was incubated for 16 h at 4°C.
Then 50 ml of a 1:1 protein G:agarose slurry (Roche) was added to
precipitate the protein±antibody complex. The immunoprecipitated
samples were electrophoresed on a 12% polyacrylamide gel and
transferred to PVDF. The labeled Smad3 was visualized by exposure to
X-ray ®lm for 6 h at ±70°C. The membrane was then blocked with
TBST + 3% nonfat milk. To stain for the presence of the FLAG peptide
the membrane was incubated with a 1:2500 dilution of monoclonal anti-
FLAG horseradish peroxidase conjugate (Sigma) for 1 h at room
temperature. The membrane was washed and the bands were visualized
as described above.
Reporter assays For the collagen promoter primary ®broblasts were
grown to 90% con¯uence in 35 mm2 plates in DMEM supplemented
with 100 U per ml penicillin/100 mg per ml streptomycin and 10% fetal
bovine serum (Mediatech). The cells were transfected with 2 mg of a
luciferase reporter construct under control of the ±300 to +54 collagen
a2(I) collagen promoter (a gift from Dr. Beniot DeCrombrugghee,
University of Texas Southwest Medical Center, Houston, TX) or the
±3200 to +54 collagen a(2)I collagen promoter (a gift from Dr.
Christine Power, Serono Pharmaceutical Research Center, Geneva,
Switzerland) and 0.5 mg of pEGFP-C1 (Clontech, Palo Alto, CA) using
Fugene6 transfection reagent (Roche) according to the manufacturer's
directions. Six hours after transfection the medium was replaced with
fresh serum-free DMEM alone or containing various concentrations of
halofuginone alone or in the presence of 10 ng per ml TGF-b. Forty-
eight hours after the addition the samples were assayed for the levels of
luciferase activity using the Bright Glow luciferase assay (Promega)
according to the manufacturer's directions.
In one set of experiments ®broblasts were grown to 90% con¯uence
in 35 mm2 plates. The cells were then transfected with 2 mg of a CAT
reporter construct under control of three tandem repeats of the A + B
box of the a2(I) collagen promoter (a gift from Dr. F. Ramirez, Mount
Sinai School of Medicine, New York, NY) and 0.5 mg of pEGFP-C1
(Clontech) using the same reagent described above. Six hours after the
transfection the cells were serum starved for 12 h in DMEM alone or
containing
10±8 M halofuginone. The ®broblasts were stimulated with 10 ng per ml
rhTGF-b1 for 48 h and the CAT protein level was determined via
enzyme-linked immunosorbent assay according to the manufacturer's
directions (Roche).
Northern blot analysis of a2(I) collagen expression Con¯uent
100 mm2 plates of TSK ®broblasts were serum starved for 16 h in
DMEM. The cells were then placed in fresh DMEM containing 10±8 M
halofuginone. Cytoplasmic RNA was extracted at various time points
using the RNeasy RNA isolation kit (Quiagen, Santa Clarita, CA)
according to the manufacturer's directions. Five micrograms of RNA
was denatured in 62% formamide, 2 3 MESA buffer (0.4 M MOPS, 0.1
M NaOAc, 10 mM EDTA), and 25% formaldehyde by heating at 65°C
for 5 min. The RNA was electrophoresed on a 1% agarose gel and
transferred to a nitrocellulose ®lter for 16 h in 2 3 sodium citrate/
chloride buffer (300 mM NaCl, 40 mM sodium citrate). The RNA was
crosslinked to the membrane in an ultraviolet oven (Stratagene, La Jolla,
CA) and probed for the presence of a2(I) collagen and b-actin mRNA
as previously described (Phelps et al, 1993).
In one set of experiments the cells were pretreated with 100 ng per
ml cyclohexamide (Sigma) for 2 h prior to the addition of halofuginone
to block protein synthesis. This concentration was experimentally found
to inhibit protein synthesis without the induction of signi®cant levels of
apoptosis (data not shown).
Statistical analysis Statistical signi®cance analysis was performed using
the unpaired Student's t test. Differences between groups were
considered to be statistically signi®cant when the p-value was 0.05.
RESULTS
Halofuginone inhibits cutaneous hyperplasia in TSK
syndrome To assess the in vivo ef®cacy of halofuginone on
®brosis we used the TSK mouse model for scleroderma. The TSK
mouse is an attractive model to study human ®brotic disease as the
animals spontaneously develop ®brosis (Green et al, 1976) unlike
other ®brosis models such as murine cGVHD and bleomycin-
induced ®brosis.
We administered 1 mg of halofuginone every other day for 60 d
to newborn and 1-mo-old TSK mice via intraperitoneal injection.
This protocol was adopted as it was previously shown to prevent
skin sclerosis in the murine cGVHD model (Levy-Schaffer et al,
1996). At the end of the treatment period skin samples were taken
for measurements of dermal thickness. Histologic analysis demon-
strated that halofuginone signi®cantly affects skin ®brosis in TSK
mice (Fig 1, Table I). The C57BL/6 mice had a dermal thickness
of 132 6 42 mm whereas TSK mice injected with PBS had a
dermis that was almost twice as thick (228 6 72 mm) (Fig 1, panels
1, 2, Table I). The administration of halofuginone signi®cantly
reduced the thickness of the dermis in both adults (p = 0.022) and
neonates (p = 0.01) compared to TSK mice injected with saline
(155 6 32 mm and 113 6 15 mm, respectively) (Fig 1, panels 3, 4,
Table I). Previously we have shown that decreased skin thickness
was paralleled by a decreased number of dermal cells expressing the
type-I collagen transcript (McGaha et al, 2001).
The effect of halofuginone on collagen synthesis by
®broblasts It has been reported that halofuginone can inhibit
in vitro collagen type I production at concentrations as low as
10±10 M (Granot et al, 1993). The effect of halofuginone on
collagen synthesis was assessed on primary culture ®broblasts
obtained from 9-d-old embryos. The level of collagen protein
present in the culture medium was assayed using a modi®ed version
of the protocol by Peterkofsky and Diegelmann (1971). It was
observed that the C57BL/6 ®broblasts seemed resistant to the
effects of halofuginone-mediated inhibition with no signi®cant
decrease in collagen production observed until the ®broblasts were
incubated with 10±8 M halofuginone (Fig 2). These results are in
agreement with previous studies, which found that ®broblasts from
non®brotic skin were more resistant to the effects of halofuginone
than the ®broblasts from animals with skin ®brosis (Levy-Schaffer
et al, 1996). It is noteworthy that halofuginone concentrations used
in the experiment did not affect ®broblast viability (data not
shown).
Decreased synthesis of collagen by halofuginone can be due to
several factors: (i) the inhibition of proliferation of ®broblasts;
(ii) the inhibition of global protein synthesis; or (iii) a selective
inhibitory effect on the synthesis of type-I collagen. To study the
effect of halofuginone on proliferation, ®broblasts were incubated
with various concentrations of halofuginone over a 72 h time
course. The data depicted in Fig 3(A) clearly show that, at
concentrations up to 10±8 M, halofuginone had no effect on
®broblast proliferation. Similarly, as can be seen in Fig 3(B), no
inhibition of overall protein synthesis was observed upon exposure
to 10±8±10±10 M halofuginone. Therefore, the halofuginone
concentrations used in the in vitro studies were apparently nontoxic
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to the cells and blocked collagen protein synthesis in a speci®c
manner.
The effect of halofuginone on the level of the collagen type I
message was studied by northern blot analysis of a2(I) collagen and
b-actin mRNAs over a 24 h time course after the addition of 10±8
M halofuginone. There was no early effect during the assay (0±4 h,
cola2(1):b-actin ratio 1.01, 0.92, and 1.01, respectively); however,
8 h after the addition of halofuginone there was a drastic reduction
in the amount of a2(I) collagen mRNA and total inhibition by 12 h
(cola2(1):b-actin ratio 0.29 and 0.008, respectively) (Fig 4A).
The kinetics of mRNA inhibition by halofuginone suggested
that protein synthesis may be necessary to block collagen type I
synthesis. To investigate this possibility, TSK ®broblasts were
preincubated with 100 ng per ml cyclohexamide for 2 h to inhibit
protein translation prior to the addition of 10±8 M halofuginone.
The ®broblasts were then assayed at 8, 12, and 24 h after the
addition of halofuginone for the presence of a2(I) collagen
mRNA. We found that cyclohexamide had no effect on the
kinetics of inhibition with a partial inhibition of a2(I) collagen
mRNA at 8 h and a total inhibition by 24 h (cola2(1):b-actin ratio
0.34 and 0.03, respectively) (Fig 4B). Cyclohexamide alone had no
effect on the production of collagen type I mRNA (data not
shown) demonstrating that the inhibition was speci®c to the
presence of halofuginone and was due to a translationally
independent mechanism.
As we established that halofuginone affected the transcript level
of the COL1A2 gene we next studied the effect of halofuginone on
collagen promoter activity of ®broblasts transfected with two
luciferase reporter constructs under control of the ±300 to +54
a2(I) collagen promoter (Fig 5A) or the ±3200 to +54 a2(I)
collagen promoter (Fig 5B), or a CAT reporter construct under
the control of three tandem repeats of the a2(I) collagen A + B box
(Fig 5C). The A + B box is a small (±330 to ±250 bp) region of the
a2(I) collagen promoter that contains several transcription factor
binding sites and has been shown to be essential for TGF-b
responsiveness of the COL1A2 gene (Zhang et al, 2000). In these
experiments 6 h after transfection the cells were treated with
increasing concentrations of halofuginone and assayed for luciferase
activity or CAT protein concentration in the cultures. There was a
highly signi®cant decrease in promotor activity upon treatment
with 10±8 M halofuginone (Fig 5). In addition, there was a high
degree of similarity between the luciferase activity and CAT
protein levels in the treated ®broblast and collagen production with
a lack of inhibition until a halofuginone concentration of 10±8 M
Table I. The effect of halofuginone on the development of
cutaneous hyperplasia
Mouse strain N Treatment Skin thickness p valuea
C57BL/6 6 PBS 132 6 42 mm ±
TSK 13 PBS 228 6 72 mm 0.02
TSK (adult) 4 HF 155 6 32 mm 0.38 (0.02)
TSK (neonate) 5 HF 113 6 14 mm 0.37 (0.01)
ap values compared various experimental groups to C57BL/6 (and untreated
TSK) mice.
Figure 1. Effect of halofuginone on dermal
®brosis. Representative histologic skin sections
from C57BL/6 mice (panel 1), TSK mice (panel
2), adult TSK mice given halofuginone
intraperitoneally (panel 3), and neonatal TSK mice
given halofuginone intraperitoneally (panel 4).
Brackets highlight the dermal area of the sections.
All sections were paraf®n embedded and stained
with hematoxylin±eosin. Scale bar: 100 mm.
Figure 2. The effect of halofuginone on collagen protein
production in normal (C57BL/6) and TSK ®broblasts. Primary
®broblast lines were incubated in serum-free medium in the presence of
increasing concentrations of halofuginone for 48 h. The amount of
secreted collagen protein was then assayed as described in Materials and
Methods. Y axis values represent CMP of collagenase-digestible protein
per 105 ®broblasts. For this ®gure open bars represent C57BL/6
®broblasts and ®lled bars represent TSK ®broblasts. Bars represent the
mean value for triplicate samples 6 SD. This experiment was repeated
four times with similar results.
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was achieved. Thus, our results show a paralleled inhibition of
message levels, promoter activity, and collagen synthesis by
®broblasts upon exposure to a halofuginone concentration of
10±8 M. It is therefore likely that halofuginone inhibits cutaneous
hyperplasia by reducing the level of collagen message via an
inhibitory effect on promoter activity of the type-1 collagen genes.
The effect of halofuginone on TGF-b-induced collagen gene
expression As we found that the halofuginone inhibited the
synthesis of collagen by ®broblasts, in further experiments we
studied its effect on TGF-b-induced collagen synthesis because it
has been shown that TGF-b plays a major role in the induction of
®brosis (McCormick et al, 1999; Nakao et al, 1999; McGaha et al,
2001). We evaluated the effect of halofuginone on TGF-b-induced
upregulation of collagen synthesis. In this experiment ®broblasts
were treated with 10±8 M halofuginone for 16 h prior to the
addition of 10 ng per ml of TGF-b. Twenty-four hours after
stimulation with TGF-b, the amount of collagen in ®broblast
cultures was assayed as described above. In the absence of
halofuginone we observed an approximately 3-fold induction in
the levels of extracellular collagen after stimulation with TGF-b
(Fig 6A), which is in agreement with the ®ndings from previous
studies. In contrast, pretreatment with halofuginone decreased the
basal levels of collagen protein synthesis in a manner similar to that
seen in Fig 2 and blocked TGF-b-induced upregulation of
collagen production ®broblasts (Fig 6A), demonstrating that
halofuginone blocks TGF-b induction of collagen synthesis. A
similar inhibitory effect was observed on promoter activity in
®broblasts transfected with the reporter constructs (Fig 6B, C). In
cultures transfected with the ±3200 to +54 bp a2(I) collagen
promoter construct there was no change in luciferase activity when
the ®broblasts were treated with 10±10 halofuginone. Unlike the
effect on basal activity, however, we observed a 50% decrease in
luciferase activity when the transfected ®broblasts were treated with
10±9 M halofuginone (2432 6 400 RLU vs 1137 6 256 RLU,
respectively, Fig 6B), and a 7-fold decrease in the luciferase levels
after treatment with 10±8 M halofuginone (2432 6 400 RLU and
352 6 85 RLU, respectively, Fig 6B). Therefore it appears that
®broblasts are more sensitive to the effects of halofuginone after
stimulation with a pro-®brotic agonist such as TGF-b.
Although this suggests that halofuginone can directly block
TGF-b responsiveness of the COL1A2 gene it is possible that these
results illustrate an overall inhibitory effect and the lack of
responsiveness to TGF-b is due to a general suppression and not
to speci®c interference with TGF-b stimulation. To test this
hypothesis we transfected ®broblasts with the CAT reporter
Figure 3. Effect of halofuginone on ®broblast
proliferation and protein production. (A) The
effect of halofuginone on cellular growth.
Fibroblasts plated in 96-well plates were incubated
for 24, 48, and 72 h with increasing
concentrations of halofuginone. At the end of the
times indicated in the ®gure the cells were assayed
for proliferation as described in Materials and
Methods. Bars represent the mean absorbance at
490 nm for triplicate wells 6 SD. This
experiment was repeated twice with similar
results. (B) The effect of halofuginone on protein
synthesis. Fibroblasts were incubated for 24 h in
increasing concentrations of halofuginone and its
effect on overall protein synthesis was determined
via incorporation of 35S-methionine. The values
represent the mean cpm per mg of precipitated
protein for triplicate samples 6 SD. This
experiment was repeated three times with similar
results. For both (A) and (B) two asterisks
represent a p < 0.02 as determined by the
unpaired Student's t test.
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construct under the control of the (A + B)3 box of the a2(I)
collagen promoter. This construct, as stated earlier, contains three
tandem repeats of the COL1A2 A + B box. This region is known
to be critical for TGF-b inducibility of the COL1A2 gene and
contains a Smad3 binding site. Therefore, inhibition of this
construct is more likely to re¯ect a direct effect on the TGF-b
response. We found that like the results with the luciferase
construct there was a dose-dependent reduction in CAT protein
levels when ®broblasts were treated with halofuginone (Fig 6C, a
1.5-fold decrease after 10±10 M halofuginone pretreatment and a
3.5-fold decrease after treatment with 10±9 M or 10±8 M
halofuginone). So it appears that halofuginone blocks TGF-b-
induced upregulation of the A + B box suggesting that
halofuginone is speci®cally blocking the TGF-b induction of the
COL1A2 gene.
Lack of effect of halofuginone on the expression of TGF-b
receptors I or II on ®broblasts We wished to determine if the
decrease in responsiveness to TGF-b was due to an inhibitory effect
of halofuginone on the level of expression of the type I and II
TGF-b receptors. Western blot analysis of lysates from ®broblasts
showed that treatment with 10±8 M halofuginone had no effect on
expression of either TGF-bR1 or TGF-bRII (Fig 7A) demon-
strating that halofuginone blocks TGF-b-induced upregulation of
collagen synthesis by some mechanism other than receptor
downregulation.
We further evaluated the effect of halofuginone on the activation
of the TGF-bR complex. To accomplish this ®broblasts were
pretreated with 10±8 M halofuginone for 24 h and then stimulated
with 10 ng per ml TGF-b for 10 or 30 min. Immunoprecipation
and western blot analysis of the TGF-bRI showed that 10±8 M
halofuginone had no effect on the kinetics or level of serine
phosphorylation (Fig 7B) demonstrating that halofuginone most
probably does not affect TGF-b-mediated upregulation of collagen
synthesis at the receptor level. Similarly, no effect was observed on
the expression or phosphorylation of the PDGF-RAA after
stimulation with its ligand, PDGF-AA, another growth factor for
®broblasts (Fig 7C).
The effect of halofuginone on the TGF-b signaling
pathway The results described above clearly demonstrate that
halofuginone exhibited a strong inhibitory effect on TGF-b-
induced collagen synthesis without affecting the expression or
activation of the TGF-b receptor. This suggests that the effect of
halofuginone may be related to intracellular events of TGF-b
signaling. Smad2 and Smad3 are considered to be the primary
signaling molecules involved in TGF-b signal transduction;
however, Smad3 has been suggested to be the primary
transcription factor associated with the regulation of type-I
collagen protein production by TGF-b (Chen et al, 1999, 2000;
Zhang et al, 2000). Therefore, we investigated the effect of
halofuginone on the activation of Smad3 and Smad2 in response to
TGF-b stimulation.
Figure 4. The effect of halofuginone on collagen type I mRNA
levels in ®broblasts. Primary TSK ®broblasts were incubated with 10±8
M halofuginone either in the absence (A) or presence (B) of 100 ng per
ml cyclohexamide. RNA was extracted over a 24 h period and 5 mg
were probed via northern blotting assay for the presence of a2(I)
collagen and b-actin mRNA. Relative intensities of the bands in (A) and
(B) were determined on digital image ®les using Quantity One software
(Biorad) according to the manufacturer's instructions. The experiment
was repeated twice with similar results.
Figure 5. Transcriptional activity of the a2(I) collagen promoter
in the presence of halofuginone. Primary ®broblasts were transiently
transfected with a luciferase reporter construct under control of the ±300
to +54 bp a2(I) collagen promoter (A), the ±3200 to +54 bp a2(I)
collagen promoter (B), or three tandem repeats of the A + B box of the
a2(I) collagen promoter controlling expression of a CAT gene. Forty-
eight hours after the addition of halofuginone cells were assayed for
luciferase activity or CAT protein levels as described in Materials and
Methods. Values were normalized for transfection ef®ciency and the bars
represent the mean value for triplicate samples 6 SD. *p < 0.05, **p
< 0.02 as determined by the unpaired Student's t test. These experiments
were repeated four times with similar results.
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We ®rst examined the nuclear translocation of Smad3. As can be
seen in Fig 8(A) nuclear extracts from ®broblasts exposed to
TGF-b showed a rapid translocation within 5 min of Smad3 to the
nucleus, reaching a maximum 30 min subsequent to TGF-b
stimulation. In contrast, pretreatment with halofuginone inhibited
the translocation of Smad3 to the nucleus. As the nuclear
translocation of Smad3 requires the phosphorylation of the protein,
we also studied the effect of halofuginone on phosphorylation of
Smad3.
To this end the ®broblasts were transfected with an expression
vector encoding FLAG-tagged Smad3. The transfected ®broblasts
were then incubated with 32P-orthophosphate to radio-label any
activated Smad3. The phosphorylation was increased upon TGF-b
stimulation demonstrating the TGF-b inducibility of Smad3
phosphorylation (Fig 8B, lane 2). The presence of halofuginone,
however, inhibited the upregulation of phosphorylation after
stimulation (Fig 8B, lanes 3, 4). This indicates that halofuginone
directly inhibits Smad3 phosphorylation thus inhibiting TGF-b
activity and ®brosis.
Further we studied whether the effect of halofuginone on
TGF-b signaling was speci®c to Smad3 or whether halofuginone
has a more pleiotrophic effect on TGF-b signaling. To address this
question TSK ®broblasts were incubated with 10±8 M halofuginone
for 16 h and then stimulated with TGF-b. The ®broblasts were
then analyzed via western blot for the phosphorylation of Smad2.
The data in Fig 8(C) show that 10±8 M halofuginone had no effect
on the expression or phosphorylation of Smad2 in response to
TGF-b stimulation. This suggests that halofuginone has a speci®c
effect on Smad3 activation.
Finally we performed EMSA analysis of nuclear lysates from
®broblasts using an oligonucleotide containing a Smad3 consensus
binding site in order to examine the effect of halofuginone on
Smad3±DNA interactions. We observed a basal level of DNA
binding resulting in major and minor shifted bands in unstimulated
®broblasts (Fig 9, arrows). The addition of TGF-b greatly increased
the intensity of the shifted bands demonstrating TGF-b inducibility
of DNA binding by Smad3. Strikingly, the pretreatment of the
®broblasts with halofuginone abrogated DNA binding in the basal
state and prevented the upregulation of DNA binding after TGF-b
stimulation (Fig 9). These data strongly suggested that halofugi-
none inhibits TGF-b-induced Smad3 activation.
Figure 6. The effect of halofuginone on TGF-b-induced collagen protein synthesis and promoter activity. (A) Primary TSK and C57BL/6
®broblast cultures were incubated in serum-free medium in the presence or absence of 10±8 M halofuginone and 10 ng per ml rhTGF-b1 for 24 h.
Extracellular collagen synthesis was then assayed as described in Materials and Methods. Y axis values represent CMP of collagenase-digestible protein per
105 ®broblasts. For this ®gure open bars represent C57BL/6 ®broblasts and ®lled bars represent TSK ®broblasts. (B) Fibroblast cultures transiently
transfected with the ±3200 to +54 bp a2(I) collagen promoter reporter construct were incubated in serum-free medium in the presence or absence of
10±8 M halofuginone and 10 ng per ml rhTGF-b1 for 48 h. The cells were then assayed for luciferase activity. (C) Fibroblast cultures transiently
transfected with the col a2(I) (A + B)3 CAT reporter construct were incubated in serum-free medium in the presence or absence of 10±8 M
halofuginone and 10 ng per ml rhTGF-b1 for 48 h. The cells were then assayed for CAT protein levels as described in Materials and Methods. For all
graphs the bars represent the mean value for triplicate samples 6 SD. *p < 0.05, **p < 0.01. All experiments were repeated at least three times with
similar results.
Figure 7. The effect of halofuginone on TGF-b receptor protein
levels and phosphorylation. (A) Fibroblast cultures were incubated in
serum-free medium in the presence or absence of 10±8 M halofuginone
and 10 ng per ml rhTGF-b1 for 16 h. Cellular lysates were generated
and probed via western blot for the presence of TGF-bRI, TGF-bRII,
or b-actin as described in Materials and Methods. (B) Fibroblast cultures
were incubated with 10±8 M halofuginone for 16 h and stimulated for 10
or 30 min with 10 ng per ml rhTGF-b. The TGF-bRI was then
immunoprecipitated using an a-TGF-bRI polyclonal antibody. The
immunoprecipitated TGF-bRI was probed via western blot for the
presence of phosphorylated serine residues as described earlier. (C)
Fibroblast cultures were incubated with 10±8 M halofuginone for 16 h
and stimulated for 10 or 30 min with 10 ng per ml rhPDGF-AA. The
PDGF-AA receptor was then immunoprecipitated using an a-PDGF
receptor polyclonal antibody. The immunoprecipitated PDGF receptor
was probed via western blot for the presence of phosphorylated tyrosine
residues as described earlier. These experiments were repeated twice with
similar results.
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DISCUSSION
Halofuginone is a drug that has been shown to have anti®brotic
activity. Although it has been shown to inhibit collagen synthesis
by ®broblasts and ®brosis in several different experimental models,
no information on activity has been forthcoming to explain the
effector mechanisms. Therefore, in this study we had two goals: (i)
to examine the in vivo ef®cacy of halofuginone in the treatment of a
spontaneous dermal ®brosis animal model and (ii) to investigate
molecular mechanisms responsible for the inhibition of collagen
synthesis by halofuginone.
For the in vivo studies, we used the TSK mouse, which
spontaneously develops a scleroderma-like syndrome consisting of
cutaneous hyperplasia, lung emphysema, heart abnormalities, and
an autoantibody pro®le similar to that seen in scleroderma (Green
et al, 1976; Rossi et al, 1984; Bona and Roth®eld, 1994). This
syndrome is due to a mutation in the ®brillin-1 gene (Siracusa et al,
1996), which is an important component of the elastic micro®brils
of connective tissue (Sakai et al, 1996). The TSK mice were given
halofuginone for 2 mo intraperitoneally and assessed for the
development of TSK syndrome. We found that halofuginone
signi®cantly decreased the skin thickness in TSK mice injected as
adults or neonates indicating an ef®cacy in treating ®brotic
conditions such as cutaneous hyperplasia associated with sclero-
derma. The decrease of ®brosis subsequent to halofuginone
treatment has been found to correlate with decreased hydroxypro-
line content in the skin and numbers of cells expressing type-1
collagen mRNA (McGaha et al, 2001) suggesting that halofuginone
inhibits dermal ®brosis by affecting type-1 collagen message levels.
In agreement with reported ®ndings (Granot et al, 1993) we
found that halofuginone inhibits collagen type I synthesis in
®broblast cultures. It is noteworthy that the inhibitory effect was
stronger in TSK than normal ®broblasts. This suggests that there is
some differential sensitivity to halofuginone via unknown mechan-
isms probably relating to the level of activity of the ®broblasts,
genetic factors, or both. Decreased synthesis of collagen by
®broblasts upon exposure to halofuginone is not related to toxicity
as 10±8 M halofuginone did not affect viability (data not shown),
growth, or overall protein synthesis by ®broblasts. These ®ndings
strongly suggest that halofuginone is a selective inhibitor of the
collagen type I genes. This concept is supported by our data
demonstrating that the decrease of collagen synthesis is paralleled by
a decrease in the level of type-I collagen transcript detectable by
northern blot.
Although it has been demonstrated that halofuginone inhibits
collagen type I mRNA synthesis, no available data exist on the
molecular mechanism of this process. Our data showed a de®nite
decrease in a2(I) collagen promoter activity mirroring the decrease
in the level of type-I collagen transcript and in collagen production.
In the promoter assay we initially used a construct containing the
±300 to +54 bp a2(I) collagen promoter. Utilizing this construct
we saw a strong inhibition of the promoter when the ®broblasts
were treated with 10±8 M halofuginone similar to what was
observed with protein synthesis; however, there was concern that
this may not re¯ect the true biologic response as it has been
reported that the type-1 collagen promoters contain many upstream
regulatory sequences (Philips et al, 1995; Chung et al, 1996; Chen
et al, 1999; Vergeer et al, 2000; Antoniv et al, 2001). Therefore we
utilized a luciferase construct containing a larger portion of the
a2(I) collagen promoter (±3200 to +54 bp). With this construct we
saw a similar pattern of inhibition so it appears that halofuginone
Figure 8. The effect of halofuginone on the activation of Smad3
and Smad2. (A) Nuclear extracts from ®broblasts were probed via
immunoblot for the presence of Smad3 over a 1 h time course following
stimulation with 10 ng per ml rhTGF-b1 in the absence (top panel) or
presence (bottom panel) of 10±8 M halofuginone. (B) Fibroblasts
transfected with a Smad3:FLAG expression vector were labeled with 32P-
orthophosphate and stimulated with 10 ng per ml rhTGF-b1 for 30 min
after a 16 h pretreatment with medium or 10±8 M halofuginone. The
Smad3 was immunoprecipitated with an a-FLAG antibody and the level
of 32P incorporation was determined via autoradiography. (C) Fibroblast
cultures were incubated with 10±8 M halofuginone for 16 h. The
®broblasts were then stimulated with 10 ng per ml of rhTGF-b1 for 10
or 30 min. The level of phosphorylation of Smad2 was then determined
via western blot as described in Materials and Methods. Relative intensities
of the bands in (B) and (C) were determined on digital image ®les using
Quantity One software (Biorad) according to the manufacturer's
instructions. These experiments were repeated twice with similar results.
Figure 9. TGF-b inducibility of Smad3±DNA interactions in the
presence of halofuginone. Fibroblasts were stimulated for 30 min with
10 ng per ml rhTGF-b1 after pretreatment for 16 h with medium (lane
4) or 10±8 M halofuginone (lane 6). Nuclear lysates were then generated
and assayed for DNA binding ability via EMSA as described in Materials
and Methods. Speci®city of the shifted bands (arrows) was demonstrated
with speci®c (lane 2) and nonspeci®c (lane 1) oligonucleotide
competitors. This experiment was repeated twice with similar results.
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inhibits a2(I) collagen synthesis at least in part by reducing the
activity of the a2(I) collagen promoter.
Halofuginone was reported to decrease collagen type I mRNA
2 h after the addition of halofuginone (Halevy et al, 1996). We did
not observe a signi®cant decrease in a2(I) collagen mRNA,
however, until 8 h after the addition of halofuginone. The lapse in
time between treatment and inhibition of collagen type 1 mRNA
indicated that protein synthesis was necessary for inhibition, and
some preliminary data supported this notion (data not shown).
Conversely, inhibition occurred with a similar time course in the
presence of cyclohexamide. Therefore it is likely that halofuginone
may directly affect transcription factors essential in collagen type I
synthesis.
We further chose to investigate the effect halofuginone had on
TGF-b induction of collagen synthesis. This was based on the key
role TGF-b is believed to play in ®brosis and collagen synthesis.
TGF-b has consistently been found to be upregulated during the
onset of ®brotic disease in humans as well as in experimental
models. In addition, recent studies have shown that the A + B box
of the human COL1A2 gene contains a Tbre (TGF-b responsive
element) and a binding site for Smad3/4. Furthermore, it appears
that this site is critical for TGF-b responsiveness of the COL1A2
gene and perhaps for overall activity of the type-I collagen
promoters (Chen et al, 1999, 2000; Zhang et al, 2000).
TGF-b is a member of an evolutionarily conserved family of
growth factors responsible for regulation of proliferation, differen-
tiation, and numerous other cellular activities including extra-
cellular matrix production (reviewed in Massague, 1998). The
receptor for TGF-b consists of a heteromeric complex containing
four type I receptors, four type II receptors, and one type III
receptor (De Crescenzo et al, 2001). Signaling via this activated
complex, however, is believed to occur through the action of the
type I and II receptors. This assembly of the activated complex
allows the phosphorylation of the type I receptor by the
constitutively active Ser/Thr-kinase activity of the type II receptor.
The receptor phosphorylation allows the subsequent association
and activation (via serine residue phosphorylation) of the TGF-b-
inducible signaling molecules Smad2/3 in the carboxy-terminal
SSXS domain (Nakao et al, 1997). The activated Smad2/3 then
associates with a cofactor used by several members of the TGF-b
superfamily (Smad4/DPC4) and is translocated to the nucleus
where the complex binds to a CAGACA promoter sequence and
transactivates TGF-b-inducible genes through a poorly understood
mechanism (Zhang et al, 1998).
We found that TGF-b stimulated a 2±5-fold increase in the level
of collagen protein and promoter activity in ®broblast cultures. This
is in agreement with previous studies, which demonstrated that
TGF-b increases the level of type-I collagen message (Ignotz et al,
1987; Raghow et al, 1987). Interestingly, treatment with 10±8 M
halofuginone inhibited the elevation of either protein or promoter
activity after stimulation with TGF-b. Therefore it appears that the
inhibitory effect cannot be overcome by pro-®brotic stimuli. It is
also of interest to note that the ®broblasts seemed to be more
responsive to the effects of halofuginone when they were
stimulated with TGF-b resulting in a dose-dependent inhibition.
To see if this inhibitory effect was speci®c to TGF-b-mediated
stimulation we used a CAT reporter construct under control of the
A + B box of the human COL1A2 promoter. The results showed
an even greater sensitivity to halofuginone with a signi®cant
inhibition of promoter activity occurring at 10±10 M and reaching
maximum inhibition of CAT protein levels at 10±9 M halofugi-
none. These data further illustrate the ability of halofuginone to
inhibit the pro-®brotic effects of TGF-b and suggest that it may
elicit its effect, at least in part, by inhibition of a TGF-b-inducible
element.
Western blot analysis of the TGF-b type I and II receptors
showed that halofuginone had no effect on their expression after a
24 h treatment so any effect halofuginone has on TGF-b signaling
is not due to receptor downregulation. It is also not likely that
halofuginone is affecting the activation or enzymatic activity of the
receptor complex as there was no change in type I receptor or
Smad2 phosphorylation.
Analysis of Smad3 induction upon TGF-b stimulation showed
that halofuginone inhibited the phosphorylation and subsequent
transcriptional activity of Smad3. How this inhibition occurs is not
clear. Halofuginone probably does not inhibit the interaction of
Smad3 with the activated receptor complex as any mechanism that
involved blocking Smad3±TGF-b receptor interactions would also
most probably block Smad2 phosphorylation due to their
homology in a C-terminal domain called the Mad-homology 2
(MH2) domain, which is responsible for Smad±TGF-b receptor
interactions (Wu et al, 2000). A more likely explanation is that a
post-phosphorylation event is responsible for the deactivation of
Smad3. Smad2 and Smad3 differ most in an N-terminal region
called the MH1 domain. This difference confers DNA binding
ability on Smad3 but not Smad2 (Shi et al, 1998) and determines
the interactions of these Smads with other transcription factors
(Labbe et al, 1998; Raman and Chen, 2000). Therefore
halofuginone may be affecting some factor that associates with
Smad3 and not Smad2 leading to deactivation of the protein.
The analysis of PDGFR-AA receptor activation after incubation
with halofuginone con®rmed that halofuginone-mediated inhibi-
tion of signal transduction is speci®c to TGF-b signaling and that
halofuginone is not a general kinase inhibitor. In future studies we
will investigate the ability of halofuginone to block other signaling
pathways induced by TGF-b stimulation, such as the MAPK
pathway, to gain a better understanding of how this drug promotes
such speci®c inhibition of collagen.
In conclusion, we demonstrated that halofuginone inhibits
dermal ®brosis in vivo via a translationally independent mechanism.
Furthermore, this inhibition appears to be the result of interference
in TGF-b-induced Smad activation and for the ®rst time demon-
strates an antagonist of TGF-b signal transduction. This suggests
that halofuginone is not only a tool to combat ®brotic disease, but
potentially possesses great value as a research tool in many areas of
cell biology.
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